[Rinsho ketsueki] The Japanese journal of clinical hematology最新文献_第8页

[Development of hematopoietic stem cell-targeted gene therapy]. [造血干细胞靶向基因疗法的发展]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2024-01-01 DOI: 10.11406/rinketsu.65.1174

Naoya Uchida

引用次数: 0

[Mitochondrial metabolism in AML cells]. [急性髓细胞白血病细胞的线粒体代谢］

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2024-01-01 DOI: 10.11406/rinketsu.65.961

Yoko Tabe

引用次数: 0

[Successful bridging therapy with alectinib prior to allogeneic stem cell transplantation for refractory ALK-positive anaplastic large cell lymphoma]. [ALK阳性难治性无性大细胞淋巴瘤异基因干细胞移植前使用阿来替尼的桥接疗法获得成功]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2024-01-01 DOI: 10.11406/rinketsu.65.158

Asuka Kono, Keisuke Tanaka, Tomohito Shimada, Kana Bando, Atsushi Takahata, Satoshi Koi, Masahide Yamamoto, Takehiko Mori, Shigeo Toyota

{"title":"[Successful bridging therapy with alectinib prior to allogeneic stem cell transplantation for refractory ALK-positive anaplastic large cell lymphoma].","authors":"Asuka Kono, Keisuke Tanaka, Tomohito Shimada, Kana Bando, Atsushi Takahata, Satoshi Koi, Masahide Yamamoto, Takehiko Mori, Shigeo Toyota","doi":"10.11406/rinketsu.65.158","DOIUrl":"https://doi.org/10.11406/rinketsu.65.158","url":null,"abstract":"Although alectinib is effective for relapsed or refractory ALK-positive anaplastic large cell lymphoma (ALCL) and has a favorable safety profile, its role as a bridging therapy for allogeneic hematopoietic stem cell transplantation (allo-HSCT) and the role of allo-HSCT itself in this setting are unknown. A 35-year-old man with ALK-positive ALCL experienced relapse after first-line therapy with CHOP. Brentuximab vedotin led to partial response and high-dose chemotherapy combined with autologous HSCT was performed. However, disease progressed 15 months after transplantation, and alectinib was initiated. Complete response (CR) was achieved after three months of treatment, and alectinib was continued for 5 months. After cessation of alectinib, allogeneic bone marrow transplantation from an HLA 1-locus mismatched unrelated donor was performed after conditioning with fludarabine, busulfan, and total body irradiation. GVHD prophylaxis consisted of tacrolimus and short-term methotrexate. The post-transplant course was unremarkable except for grade I acute GVHD. The lymphoma has not recurred for 2 years after allo-HSCT without resuming alectinib. The clinical course of our case suggests that alectinib bridging therapy and allo-HSCT are effective in relapsed/refractory ALK-positive ALCL.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"65 3","pages":"158-163"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140869682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Evidence of GVHD/GVL in allogeneic hematopoietic stem cell transplantation from sex-mismatched donors]. [性别不匹配供体的异体造血干细胞移植中 GVHD/GVL 的证据]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2024-01-01 DOI: 10.11406/rinketsu.65.265

Hideki Nakasone

{"title":"[Evidence of GVHD/GVL in allogeneic hematopoietic stem cell transplantation from sex-mismatched donors].","authors":"Hideki Nakasone","doi":"10.11406/rinketsu.65.265","DOIUrl":"https://doi.org/10.11406/rinketsu.65.265","url":null,"abstract":"Hematopoietic cell transplantation (HCT) is considered a curative treatment for hematological malignancies. However, HCT recipients often face complications such as graft-versus-host disease (GVHD) and disease relapse. Clinical factors like age and HLA disparity are recognized as risks for GVHD. Notably, sex-mismatched HCT, particularly with female donors and male recipients (F→M), is reported to increase the risk of chronic GVHD. This adverse effect of F→M HCT is thought to result from allogeneic immune response against minor histocompatibility antigens encoded on the Y-chromosome of a male recipient (HY-antigens). Indeed, antibodies against HY-antigens (HY-Abs) were detected three months after F→M HCT, and the cumulative number of HY-Abs was significantly associated with increased risks of chronic GVHD and non-relapse mortality. This review focuses on F→M HCT, shedding light on its impact in several clinical settings and presenting clinical evidence of its allogeneic response, encompassing GVHD and graft-versus-leukemia (GVL) effects. Additionally, potential clinical options to mitigate adverse effects in F→M HCT will be discussed. Further investigation is required to improve clinical outcomes and understand allogenic immunological reconstitution after F→M HCT.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"65 4","pages":"265-271"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140856865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Clinical and genetic features of MDS associated with VEXAS syndrome]. [与 VEXAS 综合征相关的 MDS 的临床和遗传特征]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2024-01-01 DOI: 10.11406/rinketsu.65.255

Hiroyoshi Kunimoto

引用次数: 0

[Novel therapies for multiple myeloma]. [多发性骨髓瘤的新疗法]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2024-01-01 DOI: 10.11406/rinketsu.65.547

Masaki Ri

引用次数: 0

[Expectations and challenges for clinical application of cancer genome panels in acute myeloid leukemia]. [在急性髓性白血病中临床应用癌症基因组面板的期望与挑战]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2024-01-01 DOI: 10.11406/rinketsu.65.343

SungGi Chi

引用次数: 0

[Recent findings and advances in treatment of chronic myeloid leukemia]. [慢性骨髓性白血病治疗的最新发现和进展]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2024-01-01 DOI: 10.11406/rinketsu.65.385

Tomoiku Takaku

引用次数: 0

[Usefulness of web-based application for health surveys before and after peripheral blood stem cell harvest from healthy donors]. [健康捐献者外周血干细胞采集前后健康调查网络应用的实用性]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2024-01-01 DOI: 10.11406/rinketsu.65.321

Yosuke Makuuchi, Hiroshi Okamura, Yukari Umemoto, Akinori Nishikawa, Rie Tanaka, Akari Sato, Kazuki Sakatoku, Kentaro Ido, Mirei Horiuchi, Masatomo Kuno, Teruhito Takakuwa, Mitsutaka Nishimoto, Yasuhiro Nakashima, Mika Nakamae, Shingo Yano, Masayuki Hino, Hirohisa Nakamae

{"title":"[Usefulness of web-based application for health surveys before and after peripheral blood stem cell harvest from healthy donors].","authors":"Yosuke Makuuchi, Hiroshi Okamura, Yukari Umemoto, Akinori Nishikawa, Rie Tanaka, Akari Sato, Kazuki Sakatoku, Kentaro Ido, Mirei Horiuchi, Masatomo Kuno, Teruhito Takakuwa, Mitsutaka Nishimoto, Yasuhiro Nakashima, Mika Nakamae, Shingo Yano, Masayuki Hino, Hirohisa Nakamae","doi":"10.11406/rinketsu.65.321","DOIUrl":"10.11406/rinketsu.65.321","url":null,"abstract":"Health surveys to assess adverse events after peripheral blood stem cell harvest (PBSCH) have conventionally been conducted by phone, but phone calls are suboptimal for conducting frequent surveys. We developed a web-based application (donor app) that enables donors to inform healthcare professionals (HCPs) of their health status as an electronic patient-reported outcome (ePRO). In this prospective observational study, we compared the usefulness of this donor app to phone calls for conducting health surveys. App users reported ePRO daily, and patients called by HCPs reported their health status at least once a week when called. The observation period was from the first administration of granulocyte colony-stimulating factor to the first follow-up visit after PBSCH, excluding the hospitalization period. Each group consisted of eight donors with a median age of 32 years (range: 19-58). Nine (56.3%) were female. There were eight related donors in the phone call group and four in the donor app group. During the observation period, HCPs obtained health status reports more frequently from app users than from phone call recipients (mean proportion of days with reports made during the observation period, 27.0% vs 53.5%; p<0.05). Average time spent by the HCPs for one follow-up and total follow-ups were both significantly shorter when the donor app was used. There were no differences in donor burden or satisfaction with donation. Our study suggests that use of a donor app could provide more detailed health survey data without increasing the burden on donors and HCPs.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"65 5","pages":"321-329"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141201571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Challenges and strategies for improving efficacy in CAR-T therapy]. [提高 CAR-T 疗法疗效的挑战和策略]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2024-01-01 DOI: 10.11406/rinketsu.65.597

Ryosuke Uchibori

引用次数: 0